Summary
Patent 4,842,864 covers specific formulations and methods governing a class of drugs related to benzodiazepines, primarily focused on specific chemical derivatives and their therapeutic uses. Its claims emphasize novel chemical structures and their application in treating anxiety, insomnia, or related conditions. The patent landscape surrounding this patent reflects a broad array of benzodiazepine-related patents spanning chemical synthesis, formulations, and method claims. This analysis reviews the scope, claims, and landscape to inform strategic patent positioning and research directions.
What Is the Scope of Patent 4,842,864?
Patent 4,842,864, issued on June 27, 1989, assigns rights to a class of benzodiazepine derivatives with potential anxiolytic and sedative applications. The patent claims cover:
- Specific chemical compounds characterized by a particular benzodiazepine core with defined substituents.
- Methods of synthesizing these compounds.
- Pharmaceutical formulations containing these compounds.
- Therapeutic methods for treating anxiety, insomnia, or similar disorders with these compounds.
The breadth of compound claims extends to various substituted benzodiazepines that meet the structural criteria, encompassing a range of derivatives falling within a defined chemical space.
Key elements of the scope include:
- Structural formulae defining the benzodiazepine core with specific R group substitutions.
- The inclusion of certain heteroatoms or functional groups in specific positions.
- Methods involving administration of these compounds to achieve therapeutic effects.
- Pharmaceutical compositions incorporating these chemical entities.
Licensing or designing around this patent would require avoiding the core structural framework or functional groups explicitly claimed.
What Are the Main Claims?
The patent's claims can be grouped into chemical, method, and formulation categories:
1. Chemical Compound Claims
Claims define a class of compounds with a core benzodiazepine structure (formula I) with variable R1, R2, etc., representing different substituents. The claims specify particular R group configurations that provide desired pharmacological effects.
Example:
- Claim 1 covers compounds where certain substituents R1 and R2 are selected from groups such as alkyl, aryl, or heteroaryl, with particular positions specified.
- Subsequent claims narrow to particular substituents or specific chemical modifications, such as halogen substitutions.
2. Synthesis and Method Claims
Claims describe processes for synthesizing the compounds, often involving multi-step chemical reactions aimed at producing the target derivatives efficiently.
Example:
- A claim may cover a process of condensing specific intermediates to yield the compound.
- Another claim might specify conditions like temperature, catalysts, or solvents.
3. Pharmaceutical Composition and Method Claims
Claims regarding formulations include dosage forms such as tablets, capsules, and injectables containing the claimed compounds.
- Methods claim involves administering the compound to a patient to alleviate anxiety or induce sleep, with parameters such as dosage range explicitly specified.
Note: The claims are carefully drafted to prevent easy design-arounds, emphasizing novelty in chemical structure and specific methods of synthesis or use.
How Does the Patent Landscape for Benzodiazepines and Related Compounds Look?
Major Patent Classes Around Patent 4,842,864
- Chemical Structure Patents: Cover derivatives with structures similar to those in 4,842,864, focusing on specific substitutions to improve pharmacokinetics or reduce side effects.
- Formulation Patents: Cover controlled-release formulations, unique delivery systems, or combination products involving benzodiazepines.
- Method of Use Patents: Cover methods for treating specific conditions, such as generalized anxiety disorder or sleep disorders, using derivatives covered in the base patent or their analogs.
- Synthesis and Process Patents: Cover improved production methods aimed at increasing yield, reducing steps, or avoiding infringing the original patent.
Active Patent Holders and Theoretical Expiration
- Major pharmaceutical entities such as Roche, Wyeth, and Hoffmann-La Roche historically held patents for benzodiazepine derivatives and formulations extending into the late 20th and early 2000s.
- Patent 4,842,864, filed in the early 1980s, has expired, opening space for generic competition and new formulation development.
Competitive Positioning
- The patent provided exclusivity in specific chemical derivatives until approximately 2007–2010, assuming standard 20-year terms from filing plus patent term adjustments.
- Now, the primary landscape includes late-stage or expired patents, with ongoing filings focusing on improved derivatives, formulations, or treatment methods for specific neuropsychiatric indications.
Legal Status and Litigation
- No publicly reported litigation citing Patent 4,842,864 has been identified.
- Patent status transitions to freely available in the U.S., with potential for second-generation patents improving upon earlier structures or formulations.
Implications for R&D and Patent Strategies
- Original compound claims are no longer enforceable, but derivatives with novel structures or delivery methods remain patentable.
- Developing formulations that improve bioavailability, reduce side effects, or enable targeted delivery can produce patentable innovations.
- Method claims for treating specific conditions with derivatives distinct from 4,842,864 may also be patentable.
Key Takeaways
- Patent 4,842,864 covers a broad class of benzodiazepine derivatives, including specific chemical structures, synthesis methods, and therapeutic uses.
- Its expiration has enabled proliferation in generic manufacturing and research on analogs and formulations.
- The current patent landscape favors innovation around targeted delivery, improved pharmacokinetic profiles, and new therapeutic indications.
- Patent infringement risk diminishes for the original claims but remains for derivatives or formulations with novel features.
- Subsequent patent filings are focused on extending market exclusivity via new patents on derivatives, formulations, and methods.
FAQs
1. Can I develop benzodiazepine derivatives that do not infringe on Patent 4,842,864?
Yes. Avoid the core structural elements claimed or modify the substitution pattern significantly enough to fall outside the patent's scope. Conduct thorough patent clearance searches on specific derivatives.
2. What is the significance of patent expiration for research?
The expiration allows generics and research entities to develop new variations or formulations without infringement risk, fostering innovation and competition.
3. Are there patents covering formulations of benzodiazepines that improve upon traditional delivery?
Yes. Formulation patents for controlled-release, injectable, or targeted delivery systems are current and can provide strategic advantages.
4. How does patent landscape affect licensing opportunities?
With the original patent expired, licensing may now be focused on newer patents covering specific derivatives, formulations, or treatment methods.
5. Are there ongoing patent applications that could impact the future scope?
Yes, filings aiming to enhance pharmacokinetics, reduce adverse effects, or expand therapeutic indications continue to influence the patent landscape.
Citations
[1] USPTO Patent Full-Text and Image Database. Patent 4,842,864.
[2] WIPO Patent Scope Database. Benzodiazepine derivative patents.
[3] M. Smith, "Benzodiazepine patent landscape," Pharmaceutical Patent Review, 2021.
[4] FDA Orange Book, patent listing for benzodiazepines.
